Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats

References

• McInnes IB, Schett G. Mechanisms of disease:The pathogenesis of rheumatoid arthritis. NEJM 2011; 365:2205-2219; PMID:22150039; http://dx.doi.org/10.1056/NEJMra1004965
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Malmström V, Burkhardt H. Autoimmune priming, tissue attack and chronic inflammation - the three stages of rheumatoid arthritis. Eur J Immunol 2014; 44:1593-9; PMID:24737176; http://dx.doi.org/10.1002/eji.201444486
   PubMed Web of Science ®Google Scholar
• O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801-5; http://dx.doi.org/10.1038/nm0804-801
   PubMed Web of Science ®Google Scholar
• Von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003; 3:223-32; PMID:12658270; http://dx.doi.org/10.1038/nri1029
   PubMed Web of Science ®Google Scholar
• Xue H, Liang F, Liu N, Song XQ, Yuan F, Luo Y, Zhao X, Long J, Sun YY, Xi YZ. Potent antirheumatic activity of a new DNA vaccine targeted to B7-2/CD28 costimulatory signaling pathway in autoimmune arthritis. Human Gene Therapy 2011; 22:65-76; PMID:20695769; http://dx.doi.org/10.1089/hum.2010.110
   PubMed Web of Science ®Google Scholar
• Song XQ, Liang F, Liu N, Luo Y, Yuan F, Xue H, Tan LX, Long J, Zhao X, Sun YY, Xi YZ. Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+Treg cells and inducing Th1 toTh2 shift in both cells and cytokines. Biomedicine & Pharmacotherapy 2010; 64:463-71; PMID:20359858; http://dx.doi.org/10.1016/j.biopha.2010.01.007
   PubMed Web of Science ®Google Scholar
• Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 2014; 66:775-82; PMID:24757129; http://dx.doi.org/10.1002/art.38323
   PubMed Web of Science ®Google Scholar
• Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73:529-35; PMID:24401994; http://dx.doi.org/10.1136/annrheumdis-2013-204575
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73:510-5; PMID:24395555; http://dx.doi.org/10.1136/annrheumdis-2013-204588
   PubMed Web of Science ®Google Scholar
• Mallon S. DNA vaccines: Treatment options for autoimmune diseases. Microbiol Mol Gen 2008; 4:99-103
   Google Scholar
• Song XQ, Liang F, Liu N, Luo Y, Xue H, Yuan F, Tan LX, Sun YY, Xi CX, Xi YZ. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine 2009; 27:690-700; PMID:19095031; http://dx.doi.org/10.1016/j.vaccine.2008.11.090
   PubMed Web of Science ®Google Scholar
• Trentham DE, Dynesius-Trentham RA, Orav EJ. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261:1727-30; PMID:8378772; http://dx.doi.org/10.1126/science.8378772
   PubMed Web of Science ®Google Scholar
• Xu SQ, Liu S, Zhang W, Shen J, Liu HX, Wang RC. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Research & Therapy 2008; 11:R180
   Google Scholar
• Merrill J, Rowley MJ, Nandakumar KS, Holmdahl R. The role of collagen antibodies in mediating arthritis. Mod Rheumatol 2008; 18:429-41; PMID:18521704; http://dx.doi.org/10.3109/s10165-008-0080-x
   PubMed Web of Science ®Google Scholar
• Zhao X, Long J, Yun S, Zhang Z, Jin J, Yu K, Hao L, Dai D, Ding L, Tan L, et al. Evaluation of Humoral and Cellular Immune Responses to a DNA Vaccine Encoding Chicken Type II Collagen for Rheumatoid Arthritis in Normal Rats. Human Vaccine & Immunther 2015; 11:938-45; http://dx.doi.org/10.1080/21645515.2015.1010977
   PubMed Web of Science ®Google Scholar
• Thomas S, Luxon BA. Vaccines based on structure-based design provide protection against infectious diseases. Expert Rev Vaccines 2013; 12:1301-11; PMID:24090172; http://dx.doi.org/10.1586/14760584.2013.840092
   PubMed Web of Science ®Google Scholar
• Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011; 11:479-84; PMID:22023477; http://dx.doi.org/10.2174/156652311798192815
   PubMed Web of Science ®Google Scholar
• Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis 2011; 53:296-302; PMID:21765081; http://dx.doi.org/10.1093/cid/cir334
   PubMed Web of Science ®Google Scholar
• Liu MY, Xiangbin Wang XB, Yin CC†, Zhong Zhang Z, Lin Q, Yongsu ZHhen YS, Huang HL. Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb. Biochem J 2007; 406:237-46; PMID:17472572; http://dx.doi.org/10.1042/BJ20070149
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Wu B, Mayton L, Kim S H, Robbins P D, Wooley P H. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis 2003; 62:707-14; PMID:12860724; http://dx.doi.org/10.1136/ard.62.8.707
   PubMed Web of Science ®Google Scholar
• Butler D M, Malfait A M, Maini R N, Brennan F M, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol 1999; 29:2205-12; PMID:10427983; http://dx.doi.org/10.1002/(SICI)1521-4141(199907)29:07%3c2205::AID-IMMU2205%3e3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Navarro-Millán I, Sattui SE, Curtis JR. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther 2013; 35:1850-61; http://dx.doi.org/10.1016/j.clinthera.2013.09.015
   PubMed Web of Science ®Google Scholar
• Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013; 1:177-84; PMID:24648915
   PubMedGoogle Scholar
• Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001; 33:7-21; PMID:11310942; http://dx.doi.org/10.3109/07853890109002055
   PubMed Web of Science ®Google Scholar
• Nokelainen M. Recombinant human collagens: Characterization of type II collagen expressed in insect cells and production of types I-III collagen in the yeast pichia pastoris. Acta Universitatis OuluensisD Medica 2000; 604:1-70
   Google Scholar
• Xi CX, Tan LX, Sun YP, Liang F, Liu N, Xue H, Luo Y, Yuan F, Sun YY, Xi YZ. A novel recombinant peptide containing only two T–cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis. Molecular Immunology 2009; 46:729-37; PMID:19041137; http://dx.doi.org/10.1016/j.molimm.2008.10.016
   PubMed Web of Science ®Google Scholar
• Myers LK, Seyer JM, Stuart JM, Terato K, David CS, Kang AH, T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J Immunol 1993; 151:500-5; PMID:7686947
   PubMed Web of Science ®Google Scholar
• Myers LK, Brand DD, Ye XJ, Cremer MA, Rosloniec EF, Bodo M, Myllyharju J, Helaakoski T, Nokelainen M, Pihlajaniemi T, et al. Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology 1998; 95:631-9; PMID:9893056; http://dx.doi.org/10.1046/j.1365-2567.1998.00637.x
   PubMed Web of Science ®Google Scholar
• Luo Y, Liang F, Liu N, Xue H, Song XQ, Yuan F, Long J, Zhao X, Sun YY, Xi YZ. Potent control of acute graft-versus-host disease lethality after immunization with a novel DNA vaccine targeted to B7-1/CD28 costimulatory signaling pathway. J Immunother 2013; 36:82-92; PMID:23377669; http://dx.doi.org/10.1097/CJI.0b013e31827a6e3e
   PubMed Web of Science ®Google Scholar